<DOC>
	<DOCNO>NCT00896064</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity booster dose pneumococcal vaccine ( GSK 2189242A ) young adult . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT 00707798 )</brief_summary>
	<brief_title>Evaluation Booster Dose Pneumococcal Vaccine Formulations Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female , include , 18 41 year old time vaccination . Subjects previously participate study NCT00707798 receive one two investigational GSK2189242A vaccine formulation primary study . Written inform consent obtain subject . Free obvious health problem establish medical history , clinical examination clinical laboratory assessment enter study . Female subject nonchildbearing potential ( define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause ) may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month vaccination . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede vaccination , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccination . Planned administration/administration vaccine foreseen study protocol period start 30 day prior vaccination end one month ( minimum 30 day ) vaccination . Administration pneumococcal vaccine study vaccine period end study NCT00707798 study vaccination . Bacterial pneumonia within period end study NCT00707798 study vaccination . Invasive pneumococcal disease ( IPD ) within period end study NCT00707798 study vaccination . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection ( laboratory testing require ) . History thrombocytopenia bleed disorder . Anaphylactic reaction follow previous administration vaccine history reaction allergic disease likely exacerbate component vaccine . Current serious neurologic mental disorder . Inflammatory process know chronic active infection ( e.g . Hepatitis B , C ) . All past current malignancy ( exclude nonmelanic skin cancer ) lymphoproliferative disorder . Acute disease time enrolment/vaccination . Fever time vaccination . Fever define temperature &gt; = 37.5Â°C oral setting . Physical examination positive acrocyanosis , jaundice , splenomegaly . Acute chronic , clinically significant anaemia , pulmonary , cardiovascular , hematologic , hepatic renal functional abnormality , determine physical examination laboratory screening test , discretion investigator Administration immunoglobulins and/or blood product within three month precede vaccination plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . History chronic alcohol consumption and/or drug abuse . Other condition principal investigator judge may interfere study finding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Young adult</keyword>
</DOC>